Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma

Basit Öğe Kaydı
dc.contributor.authorGuezel, Yunus
dc.contributor.authorKoemek, Halil
dc.contributor.authorCan, Canan
dc.contributor.authorKaplan, Ihsan
dc.contributor.authorKepenek, Ferat
dc.contributor.authorEbinc, Senar
dc.contributor.authorBueyuekdeniz, Mehmet Perver
dc.date.accessioned2024-04-24T17:08:23Z
dc.date.available2024-04-24T17:08:23Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectiveIn this study, we aimed to compare the role of Ga-68-labeled FAP inhibitor (Ga-68-FAPI)-04 PET/computed tomography (CT) and F-18-fluorodeoxyglucose (F-18-FDG) PET/CT in the evaluation of primary tumor and metastases in patients diagnosed with malignant mesothelioma. Materials and methodsOur prospective study included 21 patients with histopathological diagnosis of malignant mesothelioma who underwent both Ga-68-FAPI-04 PET/CT and F-18-FDG PET/CT imaging between April 2022 and September 2022. Maximum standardized uptake value (SUVmax), metabolic tumor volume, total lesion glycolysis, tumor-to-background ratio (TBR) and highest SUVpeak (HPeak) values and lesion numbers were calculated from primary and metastatic lesions on FDG and FAPI PET/CT images. Findings obtained from FAPI and FDG PET/CT were compared. ResultsMore lesions were detected in Ga-68-FAPI-04 PET/CT compared to F-18-FDG PET/CT in primary tumor and lymph node metastases. Statistically significantly higher SUVmax and TBR values were found with FAPI PET/CT (primary lesion SUVmax and TBR, P = 0.001 and P < 0.001, respectively; lymph node SUVmax and TBR, P = 0.016 and P = 0.005, respectively). With FAPI PET/CT, upstage was observed according to tumor-node-metastasis staging in a total of seven patients including three patients with pleural origin, three patients with peritoneal origin and one patient with pericardial origin. ConclusionIn addition to the stage change with Ga-68-FAPI-04 PET/CT in malignant mesothelioma patients, a statistically significant superiority was observed in SUVmax, TBR and volumetric parameters in primary tumors and metastases.en_US
dc.identifier.doi10.1097/MNM.0000000000001702
dc.identifier.endpage639en_US
dc.identifier.issn0143-3636
dc.identifier.issn1473-5628
dc.identifier.issue7en_US
dc.identifier.pmid37114422
dc.identifier.scopus2-s2.0-85163239169
dc.identifier.scopusqualityQ3
dc.identifier.startpage631en_US
dc.identifier.urihttps://doi.org/10.1097/MNM.0000000000001702
dc.identifier.urihttps://hdl.handle.net/11468/17320
dc.identifier.volume44en_US
dc.identifier.wosWOS:001004241800008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofNuclear Medicine Communications
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFapien_US
dc.subjectFluorodeoxyglucoseen_US
dc.subjectMaximum Standardized Uptake Valueen_US
dc.subjectMesotheliomaen_US
dc.titleComparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesotheliomaen_US
dc.titleComparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu